- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Praxis Precision Medicines Inc.
Headquarters: Boston, MA, United States of America
Website: https://praxismedicines.com/...
Year Founded: 2015
Status: Public
Industry Sector: HealthTechnology
CEO: Marcio Souza, MBA
Number Of Employees: 116
Enterprise Value: $986,908,866
PE Ratio: -3.63
Exchange/Ticker 1: NASDAQ:PRAX
Exchange/Ticker 2: N/A
Latest Market Cap: $751,889,536
BioCentury | Mar 5, 2025
Product Development
A week of endpoint misses and trial halts: BioCentury’s Clinical Report
Bright spot was a slight rise in Protagonist shares on polycythemia vera results
BioCentury | Sep 4, 2024
Product Development
Clinical Report: Alnylam’s HELIOS-B details trigger market reaction
Plus: Vaxcyte pneumococcal vaccine win, and data from Recursion, Arrowhead and Praxis
BioCentury | Mar 29, 2024
Finance
Public equity report: Avalo gets makeover with PIPE, acquisition
Plus: A PIPE for CervoMed ahead of dementia readout; and Stoke, Praxis follow clinical readouts with opportunistic follow-ons
BioCentury | Mar 26, 2024
Product Development
Clinical report: Catalysts drive up shares of Viking, Stoke, Praxis
Plus readouts for Nanoscope, Axsome, Chugai, Acelyrin and Nkarta
BioCentury | Dec 21, 2023
Management Tracks
Larson leaving LianBio as CFO
Plus: Claypoole becomes CEO of Bioventus, and updates from Boston Pharma, Atlas, Quest, Scribe, 858 and more
BioCentury | Mar 4, 2023
Regulation
March 3 Quick Takes: Praxis aims to start Phase III essential tremor study despite Phase II miss
Plus: Incyte stopping Jakafi myelofibrosis combo study and updates from Exelixis, Sangamo, BMS, Veru
BioCentury | Jun 7, 2022
Finance
June 6 Quick Takes: Resilience adds $1.2B to build manufacturing capabilities
Plus Praxis tumbles on failure in MDD and updates from Arcutis, Insilico, Alectos and more
BioCentury | Apr 30, 2022
Product Development
April 29 Quick Takes: FDA lifts Finch clinical hold
Plus All Blue makes offer for Zymeworks and updates from Praxis, Innate and CytoTronics
BioCentury | Jan 21, 2022
Discovery & Translation
ToolGen’s gene editor for hemophilia A and B; plus Praxis, TellBio and more
BioCentury’s roundup of translational news
BioCentury | Jan 13, 2022
Data Byte
Voltage-gated sodium channel blocker pipeline beyond pain
Lead candidates in Phase II testing to treat seizures and irregular heart rate
Items per page:
1 - 10 of 21